Dr. Weinstock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-4245- Is this information wrong?
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2006
- Memorial Sloan Kettering Cancer CenterFellowship, Infectious Disease, 2001 - 2003
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
- George Washington University School of Medicine and Health SciencesClass of 1997
- University of ChicagoAB, Biology, With Honors, 1993
Certifications & Licensure
- MA State Medical License 2007 - 2022
- FL State Medical License 2016 - 2018
- NY State Medical License 1998 - 2009
Awards, Honors, & Recognition
- Medical Oncology Discovery Award DFCI, 2015
- Certificate of Appreciation Secretary of the Department of Health and Human Services, 2011
- Scholar-in-Training Award AACR/AFLAC, 2005
- Join now to see all
Publications & Presentations
PubMed
- Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.Karuna Mittal, Garrett W Cooper, Benjamin P Lee, Yongdong Su, Katie T Skinner, Jenny Shim, Hunter C Jonus, Won Jun Kim, Mihir Doshi, Diego Almanza, Bryan D Kynnap, Ama...> ;Communications Biology. 2024 Apr 8
- Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.Olesinski, E., Bhatia, K., Wang, C., Pioso, M., Lin, X., Mamdouh, A., Ng, S., Sandhu, V., Jasdanwala, S., Yilma, B., Bohl, S., Ryan, J., Malani, D., Luskin, M., Kallio...> ;Blood Cancer Discovery. 2024 Mar 4
- Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma.Danmei Xu, Findlay Bewicke-Copley, Karina Close, Jessica Okosun, Robert Peter Gale, Jane Apperley, David M Weinstock, Hans-Guido Wendel, Jude Fitzgibbon> ;Blood Cancer Journal. 2024 Feb 13
- Join now to see all
Journal Articles
- Outcomes After Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor LymphomaHerrera AF, Rodig, SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen Y-B, Chan WC, Cutler CS, H..., Biol Blood Marrow Transplant, 1/1/2018
- Activity of the PI3K-delta,gamma inhibitor Duvelisib in a phase I trial and preclinical models of T-cell lymphomaHorwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster ..., Blood, 1/1/2018
- Co-targeting JAK/STAT and mTORC1/ C2 signaling produces synergistic activity in Philadelphia chromosome�like acute B-cell lymphoblastic leukemiaZhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Tai C, Cavazos A, Park E, Tabe Y, Jacamo RO, Mu H, Zhao Y, Wang J, Wu S-C, Cao F, Zeng Z, Zhou J, Mi Y, Jabbour EJ, Ra..., Oncotarget, 1/1/2018
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell LymphomaDavid M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell MalignanciesDavid M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for Untreated BCR-ABL1-Positive ALL in Older AdultsDavid M. Weinstock, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Aggressive Lymphomas60th American Society of Hematology Annual Meeting - 12/1/2018
- What is the molecular basis and most promising road towards molecular targeted therapies for double-hit lymphoma?Boston, MA - 1/1/2018
- Translocation models for T-cell lymphomaBoston, MA - 1/1/2018
- Join now to see all
Other
- Modeling Human Immunity and DiseaseWeinstock D, CellPress Webinar
http://view6.workcast.net/register?cpak=6477842955389592&referrer=webinarpage
1/1/2017 - Navigating Future Challenges in Lymphoma: A Map for the Road AheadLaCasce A, Weinstock DM, The Hematologist
1/1/2015 - �Health care loans� for Hep C CureAndrew Lo, David Weinstock, Boston Globe
1/25/2016 - Join now to see all
Press Mentions
- Cancer Research with a Human TouchApril 10th, 2018
- Dana-Farber’s Bank of Patient-Derived Tumor Xenografts Gets Major Boost from NovartisMarch 7th, 2018
- Over the River and Do Some GoodNovember 22nd, 2017
- Join now to see all
Research History
- Laboratory HeadThe Weinstock Laboratory uses a range of approaches at the intersection of genetics, DNA repair, and mouse modeling to address the ontogeny, pathogenesis, and therapeutic targeting of lymphoid neoplasms.2008 - Present
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: